awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q34671658-FD4259F5-987D-483C-ABA1-E470E76F2E15
Q34671658-FD4259F5-987D-483C-ABA1-E470E76F2E15
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34671658-FD4259F5-987D-483C-ABA1-E470E76F2E15
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
P2860
Q34671658-FD4259F5-987D-483C-ABA1-E470E76F2E15
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34671658-FD4259F5-987D-483C-ABA1-E470E76F2E15
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5cfa0c17ce8852d0839fc73c2db8fd8c52888de4
P2860
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.